Navigation Links
The Novel Oral Anticoagulants Will Continue to Drive Growth in the Atrial Fibrillation Drug Market
Date:12/19/2013

rial fibrillation drug market.

The report also reveals that ChanRx's oral cardioversion agent vanoxerine will become the sales-leading antiarrhythmic drug during the forecast period, despite only launching in 2018. Vanoxerine's high efficacy, combined with its strong safety profile, will ensure strong uptake both as a cardioversion agent and as a pill-in-the-pocket therapy.

"Despite initial poor uptake following its launch, we forecast that Eliquis will become the market leader owing to its superior clinical trial data. Eliquis remains the only agent to demonstrate increased efficacy and lower rates of major bleeding versus warfarin," said Decision Resources Analyst Eamonn O'Connor, Ph.D. "Continued strong uptake of Bayer/Janssen's Xarelto, due largely to its once-daily dosing, will see Xarelto become the second best-selling agent with peak-year sales in excess of $2 billion prior to its patent expiration in the United States in 2021."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

 


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Mylan Announces Acquisition of Rights to Novel LAMA Respiratory Compound from Pfizer
2. BioLineRx Enters Clinic with Novel Treatment for Celiac Disease
3. ARGX-110, a Novel Anti-CD70 Antibody, Meets Translational Development Goals in Dose Escalation Part of Phase Ib Cancer Study
4. The Market for Non-Small-Cell Lung Cancer (NSCLC) Will Grow to $7 Billion in 2022, Fuelled by the Entry of Twelve Novel Agents
5. The Acute Coronary Syndrome 12-Month Posthospital Market Will Double by 2022, Driven by the Uptake of Novel Lipid Modifying Agents
6. Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products
7. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
8. Opportunity Exists in the U.S. for Novel Agents in Crohns Disease and Ulcerative Colitis, Owing to Discontinued Use of Leading Anti-TNF Agents Driven by Efficacy Failures
9. Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
10. Bavarian Nordic, the international novel cancer and infectious disease vaccines focused biotech, now covered by Edison.
11. FLAG Therapeutics and Duquesne University Announce Exclusive Worldwide Licensing Agreement for Novel, Dual-action Targeted Oncology Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
(Date:1/14/2014)... Emergency Critical Care, a LifeCentre partner practice, located at 165 Fort ... first in Loudoun County to receive a ... M. Barnes , Medical Director, is a well-seasoned veterinarian of more ... , are avid scuba divers. "As altitude skiers and hikers, we ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... Public/Private Sector Strategies for America,s Health Care Future (PS2) ... its report detailing how the state can reduce its ... areas that conservatively would save Florida taxpayers up to ... to identify steps the state could take that would ...
... EXTON, Pa., March 29, 2011 ViroPharma Incorporated (Nasdaq: ... Phase 2 clinical study to evaluate the safety and ... of acute antibody-mediated rejection (AMR) in recipients of donor-specific ... double blind, placebo-controlled study will evaluate the safety, tolerability ...
Cached Medicine Technology:Senate Receives Rx Blueprint Plan That Reduces Spending and Increases Quality 2ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR) 2ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR) 3ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR) 4ViroPharma Initiates Phase 2 Study of C1 Esterase Inhibitor [Human] for Treatment of Antibody-Mediated Rejection (AMR) 5
(Date:4/23/2014)... program could help doctors predict which patients might suffer ... , The program, which assesses brain scans using pattern ... and passport control, has been developed by researchers at ... by the Wellcome Trust, which used the software are ... , Stroke affects over 15 million people each year ...
(Date:4/23/2014)... showing the potential health benefits of probiotics, antioxidants and ... supplements. And the chemical industry is getting in on ... could deter growth, so the industry is responding with ... the cover story in Chemical & Engineering News ... Chemical Society. , Melody M. Bomgardner, a senior editor ...
(Date:4/23/2014)... Five for-profit and non-profit organizations in Washington will ... of Concept grants to accelerate maturation of promising ... Life Sciences Discovery Fund (LSDF) announced today. Also ... to the Washington Biotechnology & Biomedical Association (WBBA) ... the next generation of entrepreneurs and help early-stage ...
(Date:4/23/2014)... Midlife Occupational and Leisure Time Physical Activity on Mobility ... in midlife increases the risk of mobility limitation in ... This is found in a study which followed up ... was conducted at the Gerontology Research Center in Finland ... physical labor is often repetitive, wears the body and ...
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
Breaking Medicine News(10 mins):Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... , WASHINGTON, Sept. 18 In the ... is considered a "pre-existing condition" by many health insurers, today ... police officers, war correspondents, expectant fathers, pregnant women and patients ... denied health insurance policies. , , The ...
... various routes , FRIDAY, Sept. 18 (HealthDay News) -- ... the U.S. Food and Drug Administration can be safely ... new recommendations from the American Academy of Allergy, Asthma ... responses are weakened by medical treatments (such as for ...
... , SAN FRANCISCO, Sept. 18 Quantros(TM), ... healthcare industry, today announced a partnership with HealthWatch, Inc. - a ... Care, a national, not for profit quality improvement organization - to ... , , Quantros Patient Safety Center (QPSC(TM)), the ...
... Sept. 18 happier.com is a ... designed to help people not just be happier but "do happier. ... for users to make an immediate positive impact on ... by taking 4 validated tests with instant feedback on ...
... , Active sculptor and wood carver makes quick return ... six years of dialysis finally began to take a heavy toll on 84-year-old ... his art, and he was unable to travel, which is a major source ... patriarch to an expansive family. He,s the father of four, grandfather of five ...
... SHANGHAI, Sept. 18 /PRNewswire-Asia/ -- Avery Dennison Specialty Tape,Division, ... sector,introduced two new ultra-thin adhesives and a hydrocolloid and ... (Photo: http://www.prnasia.com/sa/2009/09/18/20090918839634.html ) , ... entire spectrum of wound care and for the most,demanding ...
Cached Medicine News:Health News:Pre-Existing Health 'Conditions' - Cops, Firefighters, Expectant Dads, and Those Suffering From Allergies, Acne and Toenail Fungus Are Uninsurable According to Internal Documents 2Health News:Swine Flu Shots Safe for People With Weak Immune Systems: Experts 2Health News:Swine Flu Shots Safe for People With Weak Immune Systems: Experts 3Health News:Quantros and HealthWatch Announce PSO Partnership 2Health News:Quantros and HealthWatch Announce PSO Partnership 3Health News:https://happier.com/form.htmhappier.com Launches a Personal Trainer for Your Happiness 2Health News:Kidney Transplant at 84, Chicago Artist Proves New Start Possible at Any Age 2Health News:Kidney Transplant at 84, Chicago Artist Proves New Start Possible at Any Age 3Health News:Kidney Transplant at 84, Chicago Artist Proves New Start Possible at Any Age 4Health News:Avery Dennison Introduces Advanced New Medical Dressing Technology at MEDTEC China 2009 2Health News:Avery Dennison Introduces Advanced New Medical Dressing Technology at MEDTEC China 2009 3
Manufacturer of the WellPro since 1992, ProGroup previously distributed the instrument through Denley and Labsystems. A direct replacement for the ProPette the WellPro performs serial dilutions in an...
... compatible with hood installations. ... system for 384-well plates, ... prepares large quantities of ... Wellpro also performs plate ...
... The Aquarius 384 is a ... Aquarius 384-well head is a unique ... washing using the included wash system. ... 250 microplate stacker system. Will ...
... new Nanopipetting System Genesis NPS based on ... allows you to miniaturize your assays for ... picking and direct dilutions., Furthermore it ... applications including gene expression analysis, gene mapping, ...
Medicine Products: